SHIRE CONVICTION BUY @ GS: We remove the Not Rated designation from Shire and add the shares to the Conviction Buy List with a £56 12m price target (implies 37% upside). We believe Shire’s growth potential remains meaningfully underappreciated in both current consensus estimates and valuation. On an organic basis we forecast Shire to grow 2013-18E revenue/EPS c.10%/16% (nearly 2x the sector) and to generate c.$12-13 bn in cash (2015-18E), which we believe will add c.500-600 bp to both its revenue and EPS growth outlook. Not included in our base (given mixed Phase III results) but a meaningful source of potential upside would be success for lifitegrast ($1 bn opportunity)